Budipine HCl | BY-701 | Parkinsan | CAS#63661-61-0 | CAS#57982-78-2 | Non-Dopaminergic Antiparkinsonian Drug

MedKoo Cat#: 329212 | Name: Budipine HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Budipine, also known as BY-701 and Parkinsan, is a non-dopaminergic antiparkinsonian drug. The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity.

Chemical Structure

Budipine HCl

CAS#63661-61-0 (HCl)

Theoretical Analysis

MedKoo Cat#: 329212

Name: Budipine HCl

CAS#: 63661-61-0 (HCl)

Chemical Formula: C21H28ClN

Exact Mass:

Molecular Weight: 329.91

Elemental Analysis: C, 76.45; H, 8.56; Cl, 10.75; N, 4.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

57982-78-2(free base) 63661-61-0(HCl)

Synonym

Budipine Hydrochloride; BY-701; BY 701; BY701; Parkinsan

IUPAC/Chemical Name

1-(tert-butyl)-4,4-diphenylpiperidin-1-ium chloride

InChi Key

USUUKNCFNKZGEY-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H27N.ClH/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19;/h4-13H,14-17H2,1-3H3;1H

SMILES Code

CC([NH+]1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)CC1)(C)C.[Cl-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 329.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci. 2006 Oct 25;248(1-2):53-5. Review. PubMed PMID: 16784759. 2: Owen JC, Whitton PS. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. Brain Res. 2006 Oct 30;1117(1):206-12. PubMed PMID: 16996043. 3: Müller T, Kuhn W, Przuntek H. Efficacy of budipine and placebo in untreated patients with Parkinson's disease. J Neural Transm (Vienna). 2005 Aug;112(8):1015-23. PubMed PMID: 15583956. 4: Fisher A, Wang X, Cock HR, Thom M, Patsalos PN, Walker MC. Synergism between topiramate and budipine in refractory status epilepticus in the rat. Epilepsia. 2004 Nov;45(11):1300-7. PubMed PMID: 15509230. 5: Owen JC, Whitton PS. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol. 2005 Jul;145(5):587-92. PubMed PMID: 15834446; PubMed Central PMCID: PMC1576170. 6: Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):404-14. PubMed PMID: 14557918. 7: Uhr M, Ebinger M, Rosenhagen MC, Grauer MT. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci Lett. 2005 Jul 22-29;383(1-2):73-6. PubMed PMID: 15936515. 8: Przuntek H, Bittkau S, Bliesath H, Büttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol. 2002 May;59(5):803-6. PubMed PMID: 12020263. 9: Müller T, Przuntek H, Krüger R, Mackowiak A. Antiapoptotic effects of budipine. J Neural Transm (Vienna). 2004 Oct;111(10-11):1365-73. PubMed PMID: 15480843. 10: Bethke TH, Merz M, Zech K, Seiberling M, Hauschke D, Heinze H, Wurst W. Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration. Int J Clin Pharmacol Ther. 2001 Jun;39(6):259-64. PubMed PMID: 11430634. 11: Malsch U, Bliesath H, Böther K, Ramm H, Lühmann R. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine]. Fortschr Neurol Psychiatr. 2001 Feb;69(2):86-9. German. PubMed PMID: 11253562. 12: Biggs CS, Starr MS. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse. 1999 Oct;34(1):36-46. PubMed PMID: 10459170. 13: Przuntek H, Müller T. Clinical efficacy of budipine in Parkinson's disease. J Neural Transm Suppl. 1999;56:75-82. Review. PubMed PMID: 10370903. 14: Eltze M. Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. Review. PubMed PMID: 10370904. 15: Biggs CS, Fisher A, Starr MS. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Synapse. 1998 Nov;30(3):309-17. PubMed PMID: 9776134.